Mobilization of pre-existing polyclonal T cells specific to neoantigens but not self-antigens during treatment of a patient with melanoma with bempegaldesleukin and nivolumabJoshua Veatch, Stanley R. Riddell, Naina Singhi et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 9
Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).Noam E. Kopmar, Ryan D. Cassaday, Jonathan R. Fromm et al.|Journal of Clinical Oncology|2025Cited by 0
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmsAnna B. Halpern, Roland B. Walter, Ryan D. Cassaday et al.|Leukemia|2026Cited by 0